Microneedle Flu Vaccine Market driven by higher adoption of pain-free and comfortable delivery route The microneedle flu vaccine market involves the development and manufacturing of novel vaccines which employ microneedle technology for immunization against influenza viruses. Microneedle patches consist of arrays of tiny needles made from metals or polymers that are sufficiently long to penetrate the stratum corneum and deliver drugs to the epidermis and dermis layer of the skin. They offer several advantages over conventional hypodermic needles such as causing minimal or no pain, avoiding the risks of needle stick injuries, and enabling self-administration of drugs and vaccines. The microneedle flu vaccine provides a pain-free, patient-friendly method of vaccination against seasonal influenza. Global Microneedle Flu Vaccine Market market is estimated to be valued at US$ 1,547.5 million in 2023 and is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030). Key Takeaways Key players operating in the microneedle flu vaccine market are Sanofi, GC Pharma, Harro Höfliger, CosMED Pharmaceutical Co.Ltd., Micron Biomedical, Inc., LTS Lohmann Therapie-Systeme AG, Micralyne, Inc., Sorrento Therapeutics, Inc., TSRL, Inc., QUADMEDICINE, Raphas Co., Ltd., Cutanos GmbH, 3M, NanoPass, Corium, Inc., BD, FluGen, Inc., MICRODERMICS INC. These companies are actively engaged in developing advanced microneedle vaccine platforms and delivery technologies to expand geographic presence. The growing Microneedle Flu Vaccine Market Demand for pain-free and convenient vaccination methods is fueling the adoption of microneedle flu vaccines across both developed and developing regions. Various clinical studies have demonstrated the efficacy and safety profile of microneedle flu vaccine to be comparable to conventional intramuscular shots. Preference for self-administrable vaccine forms is further projected to drive the microneedle flu vaccine sales.’ Microneedle Flu Vaccine Market-https://www.coherentmarketinsights.com/market-insight/microneedle-flu-vaccine-market-2286